Porownywarka

Eptifibatide vs Desmopressin side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

EptifibatideDesmopressin

Udostępnij porównanie peptydów

Wlasciwosc	Eptifibatide	Desmopressin
Kategoria	Inne	Hormonalne
Znany tez jako	Integrilin	DDAVP, Stimate, Minirin
Zatwierdzony przez FDA	Tak	Tak
Status kliniczny	FDA Approved - Acute coronary syndrome and PCI Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	FDA Approved - Multiple indications Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Heart procedure support, clot prevention	Bedwetting, diabetes insipidus, bleeding disorders
Jak dziala	Eptifibatide is described as a reversible glycoprotein IIb/IIIa receptor antagonist on platelets. The supplied mechanism evidence links its KGD motif to receptor binding, which interferes with fibrinogen bridging between platelets and reduces aggregation. The source also reports a plasma half-life of roughly 2.5 hours, supporting a comparatively short duration of antiplatelet activity after discontinuation.	Desmopressin is described as a V2-selective vasopressin receptor agonist. In renal collecting ducts, V2 activation raises intracellular signaling that moves aquaporin water channels into place, allowing more water to be reabsorbed and producing smaller volumes of more concentrated urine. The source also notes that desmopressin has much less V1-mediated blood-vessel constriction than vasopressin. In endothelial tissue, V2 activity can increase release of stored von Willebrand factor and factor VIII, linking the same receptor system to hemostatic effects in selected bleeding disorders.
Typowe dawkowanie	Limited community data available · See research protocols	Limited community data available · See research protocols
Dawkowanie z badań	180 mcg/kg IV bolus · Up to 72 hours · IV bolus and infusion	10-40 mcg intranasal · Varies by condition · Intranasal, oral, IV, or subcutaneous
Typowy czas trwania	Up to 72 hours	Varies by condition
Podanie	IV bolus and infusion	Intranasal, oral, IV, or subcutaneous
Timing	Morning or as directed With or without food	Morning or as directed With or without food
Poziom dowodów	Zatwierdzone przez FDA	Zatwierdzone przez FDA
Mozliwe skutki uboczne	Bleeding (Reported as the most common listed effect, with a 28% figure in the source.) Major bleeding (Source reports a 3-10% range.) Hypotension +4 więcej Thrombocytopenia Allergic reactions High-risk medication per ISMP (Listed as a high-risk medication designation in the source.) FDA approved (Integrilin) (This is a regulatory or identity note from the source, not a side effect.)	Headache (Listed as common in the source.) Hyponatremia (Highlighted as a major risk.) Water intoxication (Source notes that severe cases can involve seizures.) +3 więcej Nausea Nasal congestion (Associated with spray use in the source.) Thrombotic events (Listed as rare in the source.)
Podsumowanie researchu	The supplied research summary characterizes Eptifibatide as supported by large randomized human trials. It cites PURSUIT in non-ST-elevation acute coronary syndrome, where death or nonfatal myocardial infarction was lower versus placebo, and ESPRIT in stenting, where the 30-day composite of death, myocardial infarction, or urgent revascularization was reported as about 6.8% with Eptifibatide versus 10.4% with placebo. The same evidence emphasizes bleeding as the principal tradeoff and reports that thrombocytopenia and immunogenicity were not common findings in that summary.	The source characterizes desmopressin as a long-used approved medicine rather than an experimental peptide. It reports clinical relevance in central diabetes insipidus, nocturnal enuresis, and nocturia through reduced urine production. It also describes hemostatic use because desmopressin can raise von Willebrand factor and factor VIII, with relevance to von Willebrand disease, mild hemophilia A, and some procedure-related contexts. The main safety issue emphasized is dilutional hyponatremia from retained water, with higher concern in young children and older adults according to the supplied source.
Referencje	PubMed NCBI Bookshelf +2 więcej PubMed PubMed	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Eptifibatide

Desmopressin

Kategoria

Inne

Hormonalne

Znany tez jako

Integrilin

DDAVP, Stimate, Minirin

Zatwierdzony przez FDA

Tak

Status kliniczny

FDA Approved - Acute coronary syndrome and PCI

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

FDA Approved - Multiple indications

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Heart procedure support, clot prevention

Bedwetting, diabetes insipidus, bleeding disorders

Jak dziala

Eptifibatide is described as a reversible glycoprotein IIb/IIIa receptor antagonist on platelets. The supplied mechanism evidence links its KGD motif to receptor binding, which interferes with fibrinogen bridging between platelets and reduces aggregation. The source also reports a plasma half-life of roughly 2.5 hours, supporting a comparatively short duration of antiplatelet activity after discontinuation.

Desmopressin is described as a V2-selective vasopressin receptor agonist. In renal collecting ducts, V2 activation raises intracellular signaling that moves aquaporin water channels into place, allowing more water to be reabsorbed and producing smaller volumes of more concentrated urine. The source also notes that desmopressin has much less V1-mediated blood-vessel constriction than vasopressin. In endothelial tissue, V2 activity can increase release of stored von Willebrand factor and factor VIII, linking the same receptor system to hemostatic effects in selected bleeding disorders.

Typowe dawkowanie

Limited community data available · See research protocols

Dawkowanie z badań

180 mcg/kg IV bolus · Up to 72 hours · IV bolus and infusion

10-40 mcg intranasal · Varies by condition · Intranasal, oral, IV, or subcutaneous

Typowy czas trwania

Up to 72 hours

Varies by condition

Podanie

IV bolus and infusion

Intranasal, oral, IV, or subcutaneous

Timing

Morning or as directed

With or without food

Morning or as directed

With or without food

Poziom dowodów

Zatwierdzone przez FDA

Mozliwe skutki uboczne

Bleeding (Reported as the most common listed effect, with a 28% figure in the source.)
Major bleeding (Source reports a 3-10% range.)
Hypotension

+4 więcej

Thrombocytopenia
Allergic reactions
High-risk medication per ISMP (Listed as a high-risk medication designation in the source.)
FDA approved (Integrilin) (This is a regulatory or identity note from the source, not a side effect.)

Headache (Listed as common in the source.)
Hyponatremia (Highlighted as a major risk.)
Water intoxication (Source notes that severe cases can involve seizures.)

+3 więcej

Nausea
Nasal congestion (Associated with spray use in the source.)
Thrombotic events (Listed as rare in the source.)

Podsumowanie researchu

The supplied research summary characterizes Eptifibatide as supported by large randomized human trials. It cites PURSUIT in non-ST-elevation acute coronary syndrome, where death or nonfatal myocardial infarction was lower versus placebo, and ESPRIT in stenting, where the 30-day composite of death, myocardial infarction, or urgent revascularization was reported as about 6.8% with Eptifibatide versus 10.4% with placebo. The same evidence emphasizes bleeding as the principal tradeoff and reports that thrombocytopenia and immunogenicity were not common findings in that summary.

The source characterizes desmopressin as a long-used approved medicine rather than an experimental peptide. It reports clinical relevance in central diabetes insipidus, nocturnal enuresis, and nocturia through reduced urine production. It also describes hemostatic use because desmopressin can raise von Willebrand factor and factor VIII, with relevance to von Willebrand disease, mild hemophilia A, and some procedure-related contexts. The main safety issue emphasized is dilutional hyponatremia from retained water, with higher concern in young children and older adults according to the supplied source.

Referencje

PubMed NCBI Bookshelf

+2 więcej

+2 więcej

Pełny profil